Inclusion Of Six-Year Overall Survival Data In The Eloxatin(R) (oxaliplatin Injection) Prescribing Information Granted FDA Priority Review
Feb 26th 2008Drug InformationColorectal Cancer
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and assigned priority review status to a supplemental new drug application (sNDA) that proposes changes to the Eloxatin(R) (oxaliplatin injection) prescribing information (PI) to include a six-year analysis from the MOSAIC trial.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
